Brokerages Set $115.00 Target Price for Taro Pharmaceutical Industries Ltd. (TARO)
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has been assigned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy rating.
Analysts have set a 1-year consensus target price of $115.00 for the company and are forecasting that the company will post $2.26 EPS for the current quarter, according to Zacks. Zacks has also given Taro Pharmaceutical Industries an industry rank of 39 out of 255 based on the ratings given to related companies.
A number of research analysts recently issued reports on the company. Zacks Investment Research lowered Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. TheStreet upgraded Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a report on Friday, February 15th. Finally, ValuEngine upgraded Taro Pharmaceutical Industries from a “sell” rating to a “hold” rating in a report on Thursday, January 10th.
NYSE:TARO opened at $103.91 on Tuesday. The firm has a market capitalization of $4.10 billion, a P/E ratio of 16.81 and a beta of 0.53. Taro Pharmaceutical Industries has a 12-month low of $76.93 and a 12-month high of $121.23.
Taro Pharmaceutical Industries (NYSE:TARO) last released its earnings results on Wednesday, February 6th. The company reported $2.40 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.95 by $0.45. The firm had revenue of $176.38 million during the quarter, compared to analyst estimates of $174.70 million. Taro Pharmaceutical Industries had a return on equity of 14.27% and a net margin of 46.55%. As a group, research analysts anticipate that Taro Pharmaceutical Industries will post 7.97 EPS for the current year.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Recommended Story: What are the benefits of investing in REITs?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.